/Investor DB

HealthCap — 2026 Investments

4 investments dated 2026 · listed companies and verified rows first · show all

Altay Therapeuticsaltaytherapeutics.cominOct 2026 · $37M

Altay Therapeutics develops small molecule inhibitors targeting transcription factors to treat serious diseases including facioscapulohumeral muscular dystrophy and cancer.

BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US

Ali Ozes(Founder)inOsman Ozes(Founder)inJAMES BREITMEYER(Executive Officer, Director)ERIC BJERKHOLT(Director)MIKE GREY(Director)ESTER SKLARSKY(Director)

Co-investorsCreative Destruction Lab (CDL)Fountain Healthcare PartnersGlobal BioAccess FundJude GomilaPappas CapitalSound Bioventures+4 more

AMRA Medical ABamramedical.comin𝕏Sep 2026

AMRA Medical is a global health informatics company specializing in MRI-based fat distribution and muscle composition analysis for precision medicine applications.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLinköping, SE

Magnus Borga(Co-Founder)inOlof Dahlqvist Leinhard(Chief Executive Officer, Co-Founder)in

Co-investorsIndustrifondenPfizer Venture Investments

CurifyLabs Oycurifylabs.cominSeries A · Jul 2026 · $14M

CurifyLabs develops an automated compounding system for pharmacies that uses robotics, GMP-manufactured excipient bases, and integrated quality control software to enable faster, safer preparation of customized medications.

Digital HealthHealthtechMedical DevicesHelsinki, FI

Charlotta Topelius(CEO & Founder)inNiklas Sandler TopeliusNiklas Sandler(CTO & Founder)in

Co-investorsLifeline VenturesSandwaterTesi (Finnish Industry Investment Ltd)

Neobiomicsneobiomics.euin𝕏May 2026

Neobiomics develops multi-strain food supplements rooted in academic research, with collaborations across Europe.

BiotechFoodTechHealthtechMedical DevicesWellness & FitnessStockholm, SE

Philipp Novak(Co-founder)inStefan Johansson(MD PhD, CMO)in

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.